Loss of revenue is rapid and extensive when patents expire for a pharmaceutical drug product. One means of extending the life cycle of a prescription product is to “switch” the drug to non-prescription status. This article explores the factors influencing this trend in the US, the types of drug products suitable for switch and the regulatory process to effect this change. Finally, licensing considerations are provided for suitable candidates.
November 29, 2011
LES Member Price:$0.00